This phase Ia/Ib trial is evaluating how safe, tolerable and effective a new targeted therapy is, given alone or in combination with another targeted therapy, in patients with advanced cancer.
This trial is treating patients with advanced cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors
This is a dose escalation and expansion trial. Eligible patients will be randomised to receive intravenous CS1002 as a monotherapy or in combination with a fixed 200mg dose of CS1003.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More